SM
ADMA icon

SG3 Management’s ADMA Biologics ADMA Stock Holding History

SG3 Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-74,000
Closed -$104K – 914
2021
Q4 		$104K Hold
74,000
– – ﹤0.01% 897
2021
Q3 		$84K Sell
74,000
-65,000
-47% -$91.1K ﹤0.01% 880
2021
Q2 		$222K Hold
139,000
– – 0.01% 804
2021
Q1 		$245K Buy
+139,000
New +$318K 0.01% 928

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SG3 Management's ADMA Position: Q1 2022 in Review

SG3 Management sold out of ADMA Biologics (ADMA) in Q1 2022, closing a stake of 74,000 shares — an estimated $104K sold.

SG3 Management first reported a position in ADMA in Q1 2021 and held it in 4 quarters. The position peaked at $106K in Q1 2021. 105 funds tracked by Wall St. Rank hold ADMA as of Q1 2022.

  • SG3 Management reported no remaining ADMA Biologics position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 74,000 ADMA Biologics shares in Q1 2022, an estimated $104K.
  • SG3 Management first reported a position in ADMA Biologics in Q1 2021 and held it in 4 quarters.
  • SG3 Management's ADMA Biologics position peaked at $106K in Q1 2021.
  • 105 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.